Associations - ER D538G

ER D538G ER D538G	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER D538G ER D538G	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria	H3B-6545 Sensitive: C2 – Inclusion Criteria
ER D538G ER D538G	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER D538G ER D538G	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials	SAR439859 Sensitive: C3 – Early Trials
ER D538G ER D538G	Breast Cancer Breast Cancer	ER D538G ER D538G	Breast Cancer Breast Cancer	tamoxifen + fulvestrant Sensitive: C4 – Case Studies	tamoxifen + fulvestrant Sensitive: C4 – Case Studies
ER D538G ER D538G	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ER D538G ER D538G	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	abemaciclib Sensitive: C4 – Case Studies	abemaciclib Sensitive: C4 – Case Studies
ER D538G ER D538G	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ER D538G ER D538G	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: C4 – Case Studies	palbociclib Resistant: C4 – Case Studies
ER D538G ER D538G	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER D538G ER D538G	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	AZD9833 Sensitive: D – Preclinical	AZD9833 Sensitive: D – Preclinical
ER D538G ER D538G	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	ER D538G ER D538G	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	lasofoxifene Sensitive: D – Preclinical	lasofoxifene Sensitive: D – Preclinical
ER D538G ER D538G	Breast Cancer Breast Cancer	ER D538G ER D538G	Breast Cancer Breast Cancer	AZD9496 Sensitive: D – Preclinical	AZD9496 Sensitive: D – Preclinical